Table 1.
Clinical characteristics (n = 13).
| Olaparib | Olaparib + cediranib | |
|---|---|---|
| 7 patients | 6 patients | |
| Age: median 53 (range 32–70) | 53 (32–61) | 57 (53–70) |
| Number of prior lines of therapy | 1: 6 patients | 1: 3 patients |
| 2: 1 patients | 2: 2 patients | |
| 3: 1 patients | ||
| Response rate | 57% | 83% |
| Best response | PR: 4 | PR: 5 |
| SD >4 months: 3 | SD >4 months: 1 | |
| PFS*, median | 11.2 months (3.6–16.8) | 13.8 months (7.5–22.2+) |
| BRCA1 or BRCA2 mutational status | Mutated: 4 – or unknown: 3 | Mutated: 3 – or unknown: 3 |
| Paired correlative studies | ||
| Cytokinea | 6 patients | 6 patients |
| PAR incorporationb | 6 patients | 5 patients |
| CEC/CEPc | 5 patients | 5 patients |
| DCE-MRId | 4 patients | 6 patients |
*p = 0.60 for overall comparison, eight PFS events were observed, four patients on each arm at the time of data cut-off (March 31, 2014).
aCytokine samples from one patient were missing.
bTwo patients had no optimal viable cells from the frozen samples for PAR analysis.
cThree patients had no optimal viable cells from the frozen samples for CEC/CEP analysis.
dThree patients were unable to tolerate DCE-MRIs.